Key result
The ID Now, Cobas LIAT, and Xpert Xpress Flu assays showed comparable sensitivities for influenza A (93.2%, 100%, 100%) and B (97.2%, 94.4%, 91.7%) and >97% specificity compared to CDC PCR.
Why the study?
Early diagnosis of influenza is critical for patient management and infection control, prompting a comparison of the performances of three commercially available CLIA-waived point-of-care molecular assays.
How do the ID Now, Cobas LIAT, and Xpert Xpress Flu point-of-care assays compare to CDC PCR for detecting influenza A/B in children?
Observational (n=201)
How do the ID Now, Cobas LIAT, and Xpert Xpress Flu point-of-care assays compare to CDC PCR for detecting influenza A/B in children?
The ID Now, Cobas LIAT, and Xpert Xpress Flu assays demonstrate high sensitivity and specificity for detecting influenza A and B in children, outperforming historical antigen testing.
No takes yet. Share an insight, caveat, or question.
These assays may support rapid point-of-care influenza testing; leaves open larger prospective validation across settings and seasons.
Kanwar et al. (2020) conducted an observational in Influenza A/B virus infection (n=201). ID Now, Cobas LIAT, and Xpert Xpress Flu assays vs. CDC Flu A/B PCR was evaluated on Sensitivity and specificity for Flu A and B virus detection. The ID Now, Cobas LIAT, and Xpert Xpress Flu assays showed comparable sensitivities for influenza A (93.2%, 100%, 100%) and B (97.2%, 94.4%, 91.7%) and >97% specificity compared to CDC PCR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: